PLI scheme to benefit 55 Pharma Firms: Govt

It received a total of 278 applications of which 55 applicants were selected

102
Medicine tablets
Picture: Unsplash

Last Updated on November 28, 2021 by The Health Master

The Ministry of Chemicals and Fertilisers said that a total of 55 pharma companies are set to benefit from the Production-linked Incentive Scheme (PLI) approved in February to boost domestic drug production. The financial outlay under the PLI scheme is ₹15,000 crore.

The ministry said it received a total of 278 applications of which 55 applicants were selected. The scheme called for applications under three different product categories.

The first category includes:

  • Biopharmaceuticals,
  • Complex generic drugs,
  • Patented drugs or drugs nearing patent expiry,
  • Cell-based or gene therapy drugs, 
  • Orphan drugs,
  • Special empty capsules like HPMC,
  • Pullulan,
  • Enteric etc.,
  • Complex excipients,
  • Phytopharmaceuticals.

The second category covered:

  • Active pharmaceutical ingredients,
  • Key starting materials,
  • Drug intermediates (excluding those covered under the earlier PLI scheme).

The scheme also covered, under the third category, repurposed drugs, autoimmune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs, and anti-retroviral drugs, in vitro diagnostic devices, and other drugs not manufactured in India.

The ministry said in a statement that “with this, a major thrust in investment is expected by the pharmaceutical industry which is ultimately aimed at meeting the objectives of the scheme,”

According to the ministry, companies, among others, will be the beneficiaries, like

  • Sun Pharmaceutical Industries,
  • Aurobindo Pharma,
  • Dr Reddy’s Laboratories,
  • Lupin,
  • Mylan,
  • Cadila,
  • Cipla.

The Cabinet approval, the ministry said, is in line with the strategy of ‘Aatmanirbhar Bharat’ to enhance India’s manufacturing capabilities by increasing investment and production and boosting exports in 10 sectors.

The scheme also aims to contribute to product diversification to high-value goods in the pharma sector.

“One of the further objectives of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains,” the ministry said.

High Court restrains publishing Ads in a dispute on Chyawanprash

Pharma industry seeks single window clearance system at CDSCO

WHO 2021: Model List of Essential Medicines feature updated

FSSAI: Govt reviews working of Food regulators

Russia likely to launch Sputnik Light Vaccine in India soon

NPPA extends price regulation on oxygen concentrators

NPPA will not intervene in complaints involving commercial interests

World’s biggest Vegetarian Capsules plant to come in India

2 lakh Pharmacies in India by next year: Biddano

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner